PD-L1 inhibitor 1
Modify Date: 2024-01-06 18:04:23
PD-L1 inhibitor 1 structure
|
Common Name | PD-L1 inhibitor 1 | ||
|---|---|---|---|---|
| CAS Number | 1675203-84-5 | Molecular Weight | 419.516 | |
| Density | 1.1±0.1 g/cm3 | Boiling Point | 611.4±55.0 °C at 760 mmHg | |
| Molecular Formula | C25H29N3O3 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | 323.6±31.5 °C | |
Use of PD-L1 inhibitor 1BMS-202 is an inhibitor of the PD-1/PD-L1 protein/protein interaction with an IC50 of 18 nM. |
| Name | N-[2-[[[2-Methoxy-6-[(2-methyl[1,1'-biphenyl]-3-yl)methoxy]-3-pyridinyl]methyl]amino]ethyl]acetamide |
|---|---|
| Synonym | More Synonyms |
| Description | BMS-202 is an inhibitor of the PD-1/PD-L1 protein/protein interaction with an IC50 of 18 nM. |
|---|---|
| Related Catalog | |
| Target |
18 nM (PD-1/PD-L1)[1] |
| In Vitro | BMS-202 inhibits PD-1/PD-Ll interaction, and may augment therapeutic immune response to a number of histologically distinct tumors. Blockade of the PD-1/PD-Ll ligation using antibodies to PD-Ll has been shown to restore and augment T cell activation in many systems[1]. |
| Kinase Assay | All binding studies are performed in an HTRF assay buffer consisting of dPBS supplemented with 0.1% (with v) bovine serum albumin and 0.05% (v/v) Tween-20. For the PD-l-Ig/PD-Ll-His binding assay, inhibitors are pre-incubated with PD-Ll-His (10 nM final) for 15 m in 4 μL of assay buffer, followed by addition of PD-l-Ig (20 nM final) in 1 μL of assay buffer and further incubation for 15 m. PD-L1 from either human, cyno, or mouse are used. HTRF detection is achieved using europium crypate-labeled anti- Ig (1 nM final) and allophycocyanin (APC) labeled anti-His (20 nM final). Antibodies are diluted in HTRF detection buffer and 5 μL is dispensed on top of binding reaction. The reaction mixture is allowed to equilibrate for 30 minutes and signal (665 nm/620 nm ratio) is obtained using an En Vision fluorometer. Additional binding assays are established between PD-1-Ig/PD-L2-His (20, 5 nM, respectively), CD80-His/PD-Ll-Ig (100, 10 nM, respectively) and CD80-His/CTLA4-Ig (10, 5 nM, respectively). |
| References |
[1]. Louis S. Chupak, et al. Compounds useful as immunomodulators. WO 2015034820 A1 |
| Density | 1.1±0.1 g/cm3 |
|---|---|
| Boiling Point | 611.4±55.0 °C at 760 mmHg |
| Molecular Formula | C25H29N3O3 |
| Molecular Weight | 419.516 |
| Flash Point | 323.6±31.5 °C |
| Exact Mass | 419.220886 |
| LogP | 3.99 |
| Vapour Pressure | 0.0±1.8 mmHg at 25°C |
| Index of Refraction | 1.575 |
| Storage condition | -20℃ |
| Acetamide, N-[2-[[[2-methoxy-6-[(2-methyl[1,1'-biphenyl]-3-yl)methoxy]-3-pyridinyl]methyl]amino]ethyl]- |
| N-{2-[({2-Methoxy-6-[(2-methyl-3-biphenylyl)methoxy]-3-pyridinyl}methyl)amino]ethyl}acetamide |
| PD-L1 inhibitor 1 |
| BMS-202 |